» Articles » PMID: 37660037

Pivmecillinam with Amoxicillin/Clavulanic Acid As Step Down Oral Therapy in Febrile Urinary Tract Infections Caused by ESBL-producing Enterobacterales (PACUTI)

Overview
Journal Trials
Publisher Biomed Central
Date 2023 Sep 2
PMID 37660037
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Oral treatment alternatives for febrile urinary tract infections are limited in the era of increasing antimicrobial resistance. We aim to evaluate if the combination of pivmecillinam and amoxicillin/clavulanic acid is non-inferior to current alternatives for step-down therapy in adult patients with febrile urinary tract infection.

Methods: We plan to perform an investigator-initiated non-inferiority trial. Adult hospitalised patients treated with 1-5 days of intravenous antibiotics for acute febrile urinary tract infection caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales will be randomised 1:1 to either control (7-10 days of either oral ciprofloxacin 500 mg twice daily or oral trimethoprim-sulfamethoxazole 800 mg/160 mg twice daily or intravenous ertapenem 1 g once daily, depending on sex, drug allergy, glomerular filtration rate and susceptibility testing) or intervention (10 days of pivmecillinam 400 mg three times daily and amoxicillin/clavulanic acid 500/125 mg three times daily). The primary outcome will be clinical cure 10 days (+/- 2 days) after antibiotic treatment completion. Clinical cure is defined as being alive with absence of fever and return to non-infected baseline of urinary tract symptoms without additional antibiotic treatment or re-hospitalisation (for urinary tract infection) based on a centralised allocation-blinded structured telephone interview. We plan to recruit 330 patients to achieve 90% power based on a sample size simulation analysis using a two-group comparison, one-sided alpha of 2.5%, an absolute non-inferiority margin of 10% and expecting 93% clinical cure rate and 10% loss to follow-up. The primary endpoint will be analysed using generalised estimated equations and reported as risk difference for both intention-to-treat and per protocol populations. Patients are planned to be recruited from at least 10 centres in Sweden from 2023 to 2026.

Discussion: If the combination of pivmecillinam and amoxicillin/clavulanic acid is found to be non-inferior to the control drugs there are potential benefits in terms of tolerability, frequency of interactions, outpatient treatment, side effects, nosocomial infections and drive for further antimicrobial resistance compared to existing drugs.

Trial Registration: NCT05224401. Registered on February 4, 2022.

References
1.
Skarp K, Shams A, Montelin H, Lagerback P, Tangden T . Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments. Int J Antimicrob Agents. 2018; 53(1):74-79. DOI: 10.1016/j.ijantimicag.2018.09.011. View

2.
. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

3.
Brenwald N, Andrews J, Fraise A . Activity of mecillinam against AmpC beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2006; 58(1):223-4. DOI: 10.1093/jac/dkl198. View

4.
Heikkila A . Antibiotics in pregnancy--a prospective cohort study on the policy of antibiotic prescription. Ann Med. 1993; 25(5):467-71. DOI: 10.3109/07853899309147314. View

5.
Sandberg T, Skoog G, Hermansson A, Kahlmeter G, Kuylenstierna N, Lannergard A . Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012; 380(9840):484-90. DOI: 10.1016/S0140-6736(12)60608-4. View